


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF THE FIRST GENERIC “COLISTIMETHATE
SODIUM FOR INJECTION” FOR MARKETING

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, “Colistimethate Sodium (多黏菌素E甲磺酸鈉) for Injection” (Brand name: Tianyun (天韻)), an anti-infective drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. The product was filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has been approved for marketing in the PRC.

The approved indications of Colistimethate Sodium for Injection developed by the Group include: the treatment of acute or chronic infections caused by susceptible strains of sensitive Gram-negative bacilli, especially those caused by susceptible strains of *Pseudomonas aeruginosa* and *Acinetobacter baumannii*; it can also be used for the initial treatment of serious infections suspected to be caused by Gram-negative bacteria and the treatment of infections caused by sensitive Gram-negative bacilli.

Colistimethate Sodium is a polypeptide antibiotic and had been used for the treatment of infections caused by Gram-negative bacteria since the 1970s. Starting from 2000, as the global problem concerning drug-resistant bacteria has become more serious and the development of new antibiotics has become more difficult, Colistimethate Sodium, which can be used for the treatment of infections caused by sensitive Gram-negative bacilli, especially those caused by susceptible strains of *Pseudomonas aeruginosa*, has once again received widespread attention and its clinical use has also been increasing. Colistimethate Sodium has been widely used in Japan, the United States and a number of European countries, but currently no relevant drugs have been imported into the PRC market. Colistimethate Sodium for Injection developed by the Group is the first of its kind that has obtained approval for marketing in the PRC, bringing good news to patients with infections of drug resistant Gram-negative bacteria.

With the severe lack of drugs for clinical treatment of infections of multidrug-resistant Gram-negative bacilli in the PRC, Colistimethate Sodium for Injection developed by the Group can provide patients with a more effective and economical medication option, and generate good social and economic benefits.

In addition, the active pharmaceutical ingredient (“**API**”) of Colistimethate Sodium is self-produced by the Group, which has obtained the Certification of Suitability to the Monographs of the European Pharmacopoeia (“**CEP**”) issued by the European Directorate for the Quality of Medicines and HealthCare (“**EDQM**”), and has been successively sold to Spain and other European countries. The CEP is one of the quality certifications for APIs with the highest standard in the world. Obtaining this certification indicates that the processing technology for manufacturing the relevant API has reached the international advanced standard. The approval of the Colistimethate Sodium product for marketing in the PRC will help the Group accelerate the pace of internationalization and facilitate its deployment in overseas markets.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 15 October 2021

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.